Harrow's Q2 results show promise, but high debt, market challenges, and execution risks loom. Read here for strategies to ...

At the same time, more than half of the US-listed stocks covered by Morningstar that reported earnings as of Aug. 11 beat ...

With a solid cash position and expected profitability by late 2026, Apellis stock is set for recovery. Read the latest ...

Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...

Regeneron’s shares have dropped sharply since peaking in August 2024, hurt by slowing Eylea sales due to competition from ...